Recommended Dosage of Buscopan (Hyoscine Butylbromide) for Pediatric Patients
For pediatric patients with colicky abdominal pain, the recommended dose of Buscopan (hyoscine butylbromide) is 10 mg orally for children aged 8-17 years. 1
Dosage Guidelines by Age
- For children aged 8-17 years: 10 mg orally as a single dose 1
- For children under 8 years: Limited evidence for safety and efficacy exists, and specific dosing guidelines are not well established 2
Administration Considerations
- Buscopan can be administered orally for gastrointestinal spasms and colicky abdominal pain 1
- The medication begins to work within 30 minutes, with approximately 20% reduction in pain intensity at this timepoint 3
- Maximum pain relief is typically achieved within 180 minutes, with approximately 59% reduction in pain intensity 3
Clinical Efficacy
- In randomized controlled trials, hyoscine butylbromide has shown effectiveness in treating nonspecific colicky abdominal pain in children 1
- Pain intensity decreases by approximately 55% after 3 days of treatment 3
- Abdominal pain frequency decreases by 42-50% with regular administration 3
Safety Considerations
- Adverse effects occur in approximately 27.6% of pediatric patients, though most are mild and transient 1
- No serious adverse effects have been reported in pediatric clinical trials 1
- Common side effects include:
Monitoring
- Monitor for visual disturbances, particularly in children who need to perform visually demanding tasks after administration 4
- No impairment of distance vision has been observed, but minor abnormalities in near vision may occur 4
- No routine monitoring of vital signs is required based on clinical trial data 1
Contraindications
- Caution should be exercised in patients with glaucoma, though routine questioning about glaucoma history may not be necessary 4
- Patients should be advised to seek medical attention if they experience eye pain or visual loss after administration 4
Buscopan has demonstrated comparable efficacy to acetaminophen in managing nonspecific colicky abdominal pain in children, with both medications providing clinically important pain reduction 1. Either medication can be considered for children presenting with this condition.